The present application describes novel isoxazoline of formula I or II: ##STR00001## or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, Z, U, X, Y, Z.sup.a, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-.alpha. converting enzyme (TACE), or a combination thereof.

 
Web www.patentalert.com

< NOx reduction compositions for use in FCC processes

< Multi stage selective catalytic cracking process and a system for producing high yield of middle distillate products from heavy hydrocarbon feedstocks

> Conductor-in-conduit heat sources for in situ thermal processing of an oil shale formation

> In situ thermal processing and remediation of an oil shale formation
~ 00298